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Abstract
Summary: BD is a systemic inflammatory disease with a variable vasculitis. Paediatric onset is very rare and carries
a strong genetic component. Oral ulcers and fever of unknown origin are frequent at onset and difficult to distinguish
from other inflammatory disorders; therefore, expert opinion is still mandatory to recognize the disease early.
An international expert consensus has recently proposed new classification criteria for children with BD. The
clinical spectrum of BD is heterogeneous and influenced by gender, ethnicity and country of residence. Young males
have the worst prognosis with significantly more frequent neurological, ocular and vascular involvement. BD treatment
is aimed at alleviating inflammation. Among all drugs, TNFα inhibitors have become a standard to control severe
ocular, neurological and digestive system involvement.
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Background
Behçet’s disease (BD) is a systemic inflammatory disease
involving primarily the oral and genital mucosa, skin
and eyes. BD includes a vasculitis affecting all sizes of
vessels but prominently the veins; thus, it was recently
reclassified as variable type, [1, 2]. The onset is insidious
with peak age of onset in young adulthood (25–30 years),
but also occasionally in children before the age of
16 years in 4 to 26 % of cases [3, 4]. As observed in
autoinflammatory diseases, BD attacks are recurrent and
self-limited. Neurological and ocular involvement cause
substantial functional limitation and handicaps. Large
vessel vasculitis is the leading cause of death, typically by
multiple thrombosis or pulmonary arteritis. Even though
it is considered as a single entity, the clinical presenta-
tion of BD is heterogeneous and may vary according to
sex, country of residence and age of onset [5–9]. The
underlying mechanisms causing the disease are still un-
clear and could combine both autoinflammation and
autoimmunity. The recent discovery of A20 protein
haploinsufficiency as a cause of autosomal dominant
“Behçet-like” disease strongly supports the idea that
the full spectrum of disorders meeting criteria for BD
cannot be related to a single mechanism [10].
Definition- classification of BD
The definition of BD is difficult and relies only on clin-
ical features. In addition, BD shares considerable overlap
of clinical features with other autoinflammatory disor-
ders, spondyloarthritis, and some immunodeficiencies.
The International Study Group for BD proposed the
most widely used classification in 1990: recurrent oral
ulceration (OU) at least thrice a year, as mandatory cri-
teria, associated with at least two other criteria among a
list of cutaneous and ocular symptoms, that gave a diag-
nostic sensitivity of 85 % and a specificity of 96 %
(Tables 1, 2 and 3) [11]. The relatively low sensitivity
of this classification was related to the load given to OU,
which can be absent in 5 % of patients, and to the positiv-
ity of the pathergy test, which is not applicable in all popu-
lations. In 2014 an International Team for the Revision of
the International Criteria for BD (from 27 countries) pro-
posed new criteria based on 2556 clinically diagnosed BD
patients and 1163 controls. The main changes from the
previous classification are that OU and pathergy test are
not mandatory. In addition, vascular and neurological
symptoms are listed.. A score of 4 points or more is
needed for diagnosis (Tables 1, 2 and 3) [12]. Our group
has recently published provisional classification criteria
from the largest prospective cohort ever reported for
BD in children [13]. All the clinical symptoms have
the same weight and the pathergy test is not included
(Tables 1, 2 and 3). This classification has been proposed
for the main purpose of clinical research; indeed, in
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children the number of symptoms may be too few to apply
any classification to a single patient. Finally, in most cases
the diagnosis is made provisionally on the basis of the
physician’s expertise.
Etiology/pathogenesis
The aetiology of BD is still unknown; however, it appears
to be a complex disease relying on an interaction be-
tween the genetic background and the environment. The
role of innate immunity through infectious mechanisms
has been suggested since the initial description of the
disease by Huluci Behçet. Pathogens such as herpes sim-
plex virus, streptococci, staphylococci, or Escherichia spe-
cies, and heat- shock proteins may contribute to attacks of
BD in susceptible persons via stimulation of the innate
immune system (inflammasome activation) through TLR2
and TLR4 [14–16], In addition, because OU is often the
presenting symptom of BD, the composition of the oral
mucosa and salivary microbiome is thought to be one
trigger of disease flares [17]. Improvement of dental
and periodontal hygiene has been associated with a de-
crease of oral ulcerations, and could be one factor explain-
ing the decrease of the incidence of BD in countries like
Japan and Turkey [18].
Immunology
A major feature of BD is the hyperactivity of neutrophils,
an effector cell of the innate immune system, as demon-
strated clinically by the pathergy phenomenon following
minimal trauma and needle prick, and histologically in
affected tissues. However, much is unknown about the
immunologic mechanisms contributing to pathogenesis.
Since neutrophil activation is influenced by monocytes,
NK cells, and T helper (TH) -17 cells, studies of these
effector cells in BD should yield important insights. IL-
21 dependent upregulation of TH-1 cells, increased
numbers of TH-17 cells, increased IL-17A secretion, and
decreased numbers of regulatory T cells (Tregs), have all
been demonstrated in blood and tissues of BD patients,
suggesting an important role for IL-21 in pathogenesis
[19]. A therapeutic effect of Interferon-α may be ex-
plained by its induction of memory T-cells from BD
patients to increase secretion of IL-10, which promoted
Treg responses [20]. Although not all studies have dem-
onstrated increased levels of pro-inflammatory cytokines
in active BD, inflammasome assembly and activation in
monocytes following TLR binding would induce secre-
tion of IL-1β, with secondary induction of IL-6 and
TNFα. The efficacy of inhibitors of these cytokines for
some manifestations of Behcet’s disease support their
pathogenic role (see Treatment).
Genetics
BD carries a strong genetic component. The frequency
of familial cases is reported to be 10 to 50 %, depending
of the country and age of onset [21, 22]. HLA-B5, and
more specifically its predominant suballele HLA-B51,
are associated with BD; carriage predominates in af-
fected males and is associated with a moderately higher
prevalence of genital ulcers, ocular and skin manifesta-
tions, and a decreased prevalence of gastrointestinal in-
volvement [23, 24]. Besides HLA-B51, which remains its
strongest genetic risk factor, other HLA class I alleles
such A26, B15, B27, and B56 represent independent risk
Table 1 International classifications criteria for Behçet’s disease
[11–13] - Criteria of the international study group for BD
Recurrent oral aphtosis (mandatory, seen by a physician and recurrence
at least 3 times in a year)
plus at least two of
Genital ulceration (or aphthosis, at least once)
Skin lesions (erythema nodosum, necrotic folliculitis and papulopustular
lesions, (post adolescent, not receiving steroids)
Ocular lesions (posterior uveitis, total uveitis, retinal vasculitis)
Positive pathergy test (done by needle prick (oblique insertion of 20- gauge
needle) or intradermal saline injection and read at 48h by a physician. Positive
reactions include: papula, pustula or papula with surrounding erythema)
Table 2 International classifications criteria for Behçet’s disease
[11–13] - International criteria 2014
Clinical manifestations Description Value/item
Oral aphthosis 2
Genital ulceration 2
Ocular signs Anterior uveitis, posterior uveitis,
retinal vasculitis
2




Vascular signs Arterial thrombosis, Large vein
thrombosis, phlebitis or superficial
phlebitis
1
Positive pathergy test (additional criteria) 1
Behçet’s disease diagnosis is made if the score is ≥ 4
Table 3 International classifications criteria for Behçet’s disease
[11–13] - Paediatric criteria for BD 2015
Item Description Value/item
Recurrent oral aphtosis At least 3 attacks/year 1
Genital ulceration Typically with scar 1
Skin involvement Necrotic folliculitis, acneiform
lesions, erythema nodosum
1
Ocular involvement Anterior or posterior uveitis,
retinal vasculitis
1
Neurological signs With the exception of isolated
headaches
1
Vascular signs Venous thrombosis, arterial
thrombosis, arterial aneurysm
1
Three of 6 items are required to classify a patient as having paediatric BD
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factors for BD whereas others like A03 and B49 are pro-
tective [25]. Genome wide association and next generation
sequencing analyses have demonstrated the combined role
of genes from both innate and adaptive immunity. Among
them, susceptibility loci in ERAP1, IL23R and IL10 are
shared with inflammatory bowel disease, psoriasis and
spondyloarthritis [26]. In addition, BD association with
TLR4, NOD2 and MEFV suggest bacterial and possible
other danger sensing mechanisms in BD pathogenesis [27].
An epigenome-wide study of DNA methylation has pro-
vided evidence that epigenetic modification of cytoskeletal
dynamics underlies BD pathogenesis [28]. Reinforcing the
diversity of the disease mechanisms, a novel autoinflamma-
tory disease with a BD-like phenotype (recurrent OU and
GU, eye inflammation and axillary abscesses) has been
reported in association with haploinsufficiency of A20 pro-
tein, a regulator of NFKB activation [10].
Epidemiology
The geographic distribution of BD is spread along the
former Silk Road from the Far East to the Mediterranean
basin. As a result, the highest prevalence has been re-
ported in Northern China and Iran (100 per 100,000),
Turkey (80–370.0 per 100,000) and the Turkish German
population (77 per 100,000). In contrast, BD occurs
more rarely in Western Europe with a prevalence of 0.1
per 100,000 in Sweden, 7.1 per 100,000 in France and
15.9 per 100,000 in Southern Italy [29–34]. Besides
the country of residence, ethnic background is im-
portant, and an epidemiological study performed in
the Paris area has shown that the prevalence of BD
in immigrants of North African or Asian ancestry is
significantly higher than that in the European-origin
population [32]. The same phenomenon was observed
in Germany [34].
The usual age at BD onset is around 30 years; however,
there are numerous observations and case series of paedi-
atric cases. The prevalence of BD in children is unknown
but is probably very low, as a range of 3.3 to 26 % of cases
has been reported [30, 35]. The international PEDBD co-
hort study of 156 patients has shown a mean (±SD) age of
BD onset (at first symptom) of 7.83 (±4.39) years, in
accordance with previous series [6, 7, 35, 37]. Paediatric
patients have generally few symptoms, and the time to
diagnosis is long - between 3 and 5 years [4, 6, 7, 36]. Fa-
milial aggregation is high in paediatric BD, and has been
observed in 9 to 42 % of cases [13, 21, 22, 37]. Previous
studies had reported variations regarding the sex ratio of
BD, with female predominance in Asian populations and
male predominance in Middle Eastern and Mediterranean
countries. The most recent epidemiological studies tend
toward an equal sex ratio, as currently observed in paedi-
atric BD, but with significant phenotypic differences ac-
cording to gender. Indeed, severe uveitis, vascular disease
and mortality occur more frequently in males whereas
genital aphthosis and erythema nodosum are more fre-
quent in females [6, 7, 38–40].
Clinical symptoms
Fever
Recurrent fevers are scarcely documented (22 %) in the
adult BD population where they correlate with vascular,
neurological or joint involvement [41]. Recurrent fevers
were not significantly associated with the diagnosis of
BD in the PEDBD cohort, but they were present in 44 %
(68/156) of patients. At this age, if fever remains a
calling symptom of severe vascular and neurological
disease, it is also observed in association with attacks
of oral aphthosis in a clinical presentation resembling
Periodic Fever, Aphthosis, Pharyngitis, and Adenitis
(PFAPA) syndrome [42].
Mucocutaneous lesions
Recurrent OU is not exceptional in the general paediat-
ric population, but remains a major clue for the diagno-
sis of BD. ROU is the presenting symptom in 87 to 98 %
of cases and is present in almost all patients with BD
(95 %) (Table 4). BD-related OU do not differ from other
OU. They are discrete, round or oval ulcers with a
yellow-gray pseudomembranous base and a brightly ery-
thematous halo (aphthae); they involve the lips, tongue,
cheeks, and palate and disappear without scar. All varia-
tions are possible: single, multiple, herpetiform and nec-
rotic, from minor to major. Lesions are painful and may
interfere with eating, speaking, or swallowing. Minor le-
sions heal between 7 and 10 days but major lesions may
evolve over weeks. When they are isolated, a large differ-
ential diagnosis is necessary to rule out numerous other
causes of ROU, including autoinflammatory diseases, in-
flammatory bowel diseases (IBD) and immunodeficiency.
OU may be the only manifestation of disease for an
average of 6 to 7 years before the second major mani-
festation is apparent [43, 44]. GU is observed in 55 to
83 % of children with BD, which is less than in the adult
population (80 to 90 %). In the PEDBD study they ap-
peared at a mean (±SD) age of 11.23 ± 4.32 years [13].
The lesions are usually larger and deeper than OA and
have an irregular margin [15]. They are located typically
on the vulva and the scrotum; in children, skin aphthae
over the perianal region has been observed in 7 % of pa-
tients [7], and must be distinguished from anal aphthosis
which is more related to IBD. In children, the combin-
ation of OU plus GU is not sufficient to confirm the
diagnosis of BD. (Tables 1, 2 and 3). Other cutaneous
symptoms are very frequent in BD; in the PEDBD cohort
they appeared later than OU, at a mean age of 10.36
(±4.30) years. Symptoms associated with PEDBD classifi-
cation were necrotic folliculitis, and acneiform lesions
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more commonly in males, and erythema nodosum more
commonly in females [6]. These lesions appear often in
combination and primarily involve the buttocks and the
lower limbs. Other neutrophilic rashes may also be ob-
served as well as lesions corresponding to superficial
thrombosis (dermal nodules). The skin of patients with
BD is irritable at puncture, minor trauma and shaving.
The pathergy test, using a 24 gauge needle puncture,
was formerly used to demonstrate skin hypersensitivity
(pustula in 24 to 48 h) [11]. However the positivity of
this test varies from 40 to 80 % according to the studied
population. The pathergy test is no longer mandatory to
define BD in adults, and is not retained as a criterion for
BD in children [13].
Joint involvement
Oligo and polyarthritis develop in half of adult patients
[45]. Twenty to forty percent of children with BD have
some articular involvement, generally arthralgia in few
joints (knees, ankles, elbows and wrists). Joint symptoms
were present in 50 % (78/156) of definite BD patients in
the PEDBD study. Axial arthritis was reported in
16.67 % (26/156, which is rather high), and peripheral
arthritis in 47.44 % (74/156) [13]. The course is recur-
rent. Association with HLA- B27 spondylarthropathy is
seen in 2 % of patients.
Eye involvement
Bilateral posterior uveitis with retinal vasculitis is the most
typical feature of ocular-BD. In this case, patients usually
have a painless, bilateral decrease in visual acuity [15].
The mean (±SD) age of onset of uveitis was 10.94 ±
3.62 years in the PEDBD cohort [13]. Anterior uveitis
could be more frequent before the age of ten years in asso-
ciation with familial aggregation but panuveitis could start
later. Intermediate uveitis is rare. Uveitis may be the
presenting symptom of BD in 10 % of cases, and it has
been recognised that patients with uveitis suffer gener-
ally less of OU. In a Tunisian retrospective survey of 62
patients (111 eyes), panuveitis (68 eyes, 61.3 %) and
posterior uveitis (38 eyes, 34.2 %) were the most common
forms, followed by anterior uveitis (five eyes, 4.5 %).
Retinal vasculitis was found in 89 eyes (80.2 %) [46].
The most common complications included posterior
synechiae (32.4 %), cataract (31.5 %), and cystoid macular
edema (19.8 %). Similar findings were observed in adult
and childhood uveitis from several case series [47-49]. In
the PEDBD registry at a mean of 5 years of follow up, vis-
ual acuity was decreased to <1/10 (equivalent to <20/200
by Snellen test) in 16.6 % (26/156) of patients, which
represented 33.3 % (26/78) of patients with ocular in-
volvement [13]. The occurrence and severity of uveitis
is associated with the male sex, generally after the age
of ten years [48, 49].
Table 4 Frequencies of clinical characteristics of BD in children compared to adults
Paediatric series Adult series
Clinical features in % Karincaoglu [4] Krause [37] Koné- Paut [7] Atmaca [35] Koné-Paut + [13] Alpsoy E [38] Krause [37]
N = patients 33 19 65 110 156 661 34
Oral aphthosis 100 100 96 100 100 100 100
Genital aphthosis 82 31.6 70 83 55 58.3 88.2
Cutaneous signs 89.5 92 76 82.4
Erythema nodosum 52 36.8 40 37 22.7 44.2 26.5
Pseudo folliculitis 51 8/19 58 39 43 55.4 ND
Pathergy test + 37 41.2 - 45.5 NS 37.8 57.1
Ocular signs 35b 60 45 29.2 Approx 50 %
Anterior uveitis 47.4 31 30.1 47.1
Posterior uveitis 42.1 36 9 % 28 8.8
Retinal vasculitis 10.5 16.7
Arthralgia/arthritis 40 47.4 56 22 41 33.4 17.6
Gastro intestinal 4.8 36.8 14 NS 4.49 1.6 11.7
Neurologicala 7.2a 26.3 15 3.6a 5a 3a 5.8a
Vascular 9.6 10.5 15 3.6 15.38 4.4 26.5
Family history of BD 19 ND 15 12 24.4 ND ND
Age first symptom (years) 12.3 (1–16) 6.9 ± 3.9 8.4 (0–16) 11.6 (1–16) 7.83 ± 4.39 ND 30.4 ± 8
aOther than headaches buveitis without details + in this study patienst were classified by an international expert committee, independently of the
international criteria
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Neurological involvement
Neurologic involvement is newly considered in the def-
inition of BD and occurs in 5.3 to 59 % of adult cases
[50]. Chronic headaches are frequent in patients with
BD, and may be either isolated or associated with severe
NBD involvement [51]. In the PEDBD study, although
not considered as a classification criterion, the presence
of headaches was significantly associated with BD
confirmation by the experts (p = 0.0063) [13]. NBD
manifestations include acute and chronic progressive
manifestations, especially in young males with early
onset of disease. Acute manifestations include recurrent
aseptic meningitis and meningoencephalitis. The CSF
examination shows elevated protein levels, and pleocytosis
consisting of both polymorphonuclear cells and lympho-
cytes [15]. Acute manifestations are generally relapsing
but responsive to steroids. Parenchymal lesions are located
in the brainstem, and multiple high-intensity focal lesions
in the brainstem, basal ganglia, and cerebral white matter
are typical findings on T2-weighted MRI [15, 50, 52, 53].
Patients present with acute headaches, bilateral papil-
ledema and hemiparesis accompanied with signs of
brainstem involvement (ataxia, pyramidal and extrapyr-
amidal syndrome, epilepsy, and cranial nerve involve-
ment). Chronic progressive lesions are parenchymal and
vascular. They manifest as various neuropsychiatric distur-
bances such as cognitive impairment, memory loss, de-
pression, anxiety, pseudobulbar syndrome and definite
sensitive and motor deficits. These impairments are gener-
ally irreversible [15, 50]. Other lesions not classified as
parenchymal or vascular are seldom observed, like
myositis (myopathy) and peripheral neuropathy. The
frequency of NBD in children ranges from 15 to 30 %
and increases up to 50 % considering isolated headaches
which can be the presenting symptom of BD in up to
25 % of reported cases [13, 53]. The main manifestations
at the paediatric age are cerebral venous thrombosis, and
cranial nerve palsy (especially the VI th nerve), rather than
parenchymal lesions. The rate of neurologic sequelae
reached (75 %) in one study, and had long-term conse-
quences on children’s schooling. Half of the NBD children
could not follow a normal curriculum and 50 % of the
remainder needed extra school arrangements to be main-
tained in normal school system [53].
Vascular involvement
BD affects any type and size of vessel, and was recently
classified as “variable” vasculitis [1]. The vascular in-
volvement is now integrated in both the adult and the
paediatric BD classification criteria. The main pathologic
feature is an inflammation of the vessel wall leading to
thrombus formation. Activated neutrophils produce ex-
cessive superoxide anion radicals and lysosomal enzymes
that induce lesions of the vessel wall. Endothelial
damage with aneurysm formation causes local blood
flow abnormalities. The thrombus is usually adherent
and does not generate secondary embolism. In a French
retrospective cohort study of 807 BD patients 36.7 %
(296 patients, 73.3 % male, median age 30 years) had
venous thrombosis. Deep vein thrombosis of the legs
was the most frequent vascular event (55 %); 10.9 % had
vena cava involvement, 9.7 % pulmonary artery involve-
ment, 2.2 % cervical vein thrombosis, and 2.4 % Budd-
Chiari syndrome [54]. At 5 years the mortality rate was
6.4 % without immunosuppressive treatment. The fre-
quency of relapse is high; in a Turkish study, first vas-
cular relapse developed in 32.9 % of patients and the
time interval between the first and second vascular
event was 25.5 (1–252) months [55]. In children, if the
condition per se is a risk for vascular activation, male pa-
tients are predominantly affected (SR 6/1) and many
patients may accumulate other factors of thrombophilia
such as anticardiolipin antibodies and protein C deficiency
[56]. The frequency of vascular involvement is reported to
be 5 to 20 % in paediatric series of BD (Table 4). In a series
of 47 adults with pulmonary artery vasculitis, the presen-
tation was usually haemoptysis (79 % of cases) associated
with cough, fever, dyspnea, and pleuritic chest pain. The
major risks were aneurysm and/or thrombus formation
with secondary rupture or embolism, which generally
evolved in patients with active extra-pulmonary disease.
After a mean follow-up of 7 years, 12 of 47 (26 %) patients
were dead, especially those with the larger aneurysms [57].
Digestive involvement
Gastrointestinal (GI) involvement of BD is a challenging
situation, which raises the possibility of another IBD. In
children, GI symptoms occurred in 40.38 % (61/156) of
patients in the PEDBD study, and were essentially iso-
lated abdominal pain or discomfort. Other symptoms
were digestive aphthae 4.49 % (7/156), bleeding 2.56 %
(4/156), and perforation (one case) [13]. The most severe
cases of GIBD are reported from Japan and Korea with a
frequency of 40 %. The clinical symptoms of colitis have
no specificity: bloody diarrhoea, nausea, fever, weight
loss. Lesions may involve the whole digestive tract from
the mouth to the anus. The ileum and the colon are the
most commonly involved intestinal sites. Deep aphthous
and necrotic ulcerations lead to abscesses and perfor-
ation requiring surgery.
Miscellaneous involvement
Pulmonary involvement affects primarily the pulmonary
arteries, usually at multiple sites, but parenchymal lesions
such as nodules and cavities are reported. Pleural effusions
and mediastinal lymphadenopathy are also part of BD;
however, ruling out infectious causes is mandatory [57].
BD vasculitis involves the aorta, the sinuses of Valsalva,
Koné-Paut Pediatric Rheumatology  (2016) 14:10 Page 5 of 8
and the coronary arteries [58]. Pericarditis is common,
variably manifesting as recurrent, hemorrhagic, or small
asymptomatic pericardial effusion. Myocarditis and intra-
cardiac thrombus are also seen occasionally. BD-associated
diseases include several types of glomerulonephritis, cres-
centic glomerulonephritis and IgA nephropathy being the
most common [59]. Tubulointerstitial nephropathy is rare.
AA amyloidosis has decreased with time and better man-
agement of BD. Orchitis, epididymitis, urethritis and sterile
cystitis are rare.
Disease course and prognosis
The course of BD is recurrent and unpredictable. In
children the disease remains often active with new
symptoms appearing with time. Functional impairments
are related to neurological and ocular disease. In adults
BD symptoms usually decrease with time after a mean
follow up of ten years. In a single-center retrospective
cohort of 817 children and adults followed for a median
of 7.7 years, the mortality rate was 5 %. Vascular disease
was the main cause of death, (43.9 % of deaths), followed
by malignancy (14.6 %), CNS involvement, (12.2 %) and
sepsis (12.2 %). Death was associated with younger age
(15–25 years), male sex, arterial involvement, and a high
number of flares [39].
Value of biological exams
The acute phase reactants, i.e. CRP and ESR, may not be
modified, except in case of active serositis, cerebral in-
volvement or vasculitis. BD cannot be ruled out in the
absence of the antigen HLA-B51.
Treatment
The treatment of BD is aimed at relieving inflammation.
The treatment of BD in children follows the 2009 inter-
national recommendations [60]; of interest, none of
these treatments have been currently approved by the
FDA or EMA for the indication of BD. Colchicine is
widely used to control recurrent oral and genital ulcer-
ation; however, no studies have provided evidence to
demonstrate its efficacy. Short courses of systemic ste-
roids may help alleviate severe mucous ulcerations but
cannot be used on a long-term basis. Other therapeutic
options for chronic lesions include topical steroids and
analgesics, oral azathioprine, and TNFα inhibitor treat-
ments. Oral thalidomide is an effective treatment but its
use is limited by its frequent neurological toxicity [61].
In a recent phase II placebo-controlled study of 111 BD
patients with recurrent OU, Apremilast (Otezla®), an oral
phosphodiesterase-4 inhibitor, reduced significantly the
mean (±SD) number of oral ulcers per patient at week
12, compared to placebo (0.5 ± 1.0 vs. 2.1 ± 2.6) (P < 0.001)
[62]. Severe vascular, neurologic or ocular involvement re-
quires a combination of steroids and immunosuppressive
treatment (azathioprine, cyclosporine, cyclophosphamide).
Among them, azathioprine is still widely used as steroid
sparing treatment. TNF-α inhibitors have become stand-
ard treatment of severe neurological, digestive and ocular
involvement for patients resistant to conventional immu-
nosuppressants [63]. Several reports have mentioned the
use of anti IL1 (anakinra, canakinumab) and anti IL6
blockers (tocilizumab) with various results in treating se-
lective manifestations of BD, and two exploratory phase II
studies have shown efficacy and safety of Gevokizumab in
patients with steroid dependant uveitis [64–67]. The use
of anticoagulants in treating BD thromboses is still con-
troversial and no studies have demonstrated their efficacy
in comparison to immunosuppressive treatment [68].
Conclusions
BD is still a difficult disease in terms of both diagnosis
and treatment. The new paediatric classification criteria
may increase the opportunity of therapeutic trials in
paediatric patients, however they need further validation.
The use of anti TNFa treatment has become a standard
for severe ocular, neurological and digestive
involvement.
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